Rituximab or a second anti–tumor necrosis factor therapy...

Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register

Moetaza M. Soliman, Kimme L. Hyrich, Mark Lunt, Kath D. Watson, Deborah P. M. Symmons, Darren M. Ashcroft, on behalf of the British Society for Rheumatology Biologics Register
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
64
Year:
2012
Language:
english
Pages:
1
DOI:
10.1002/acr.21663
File:
PDF, 142 KB
english, 2012
Conversion to is in progress
Conversion to is failed